Marinol

Acquired Immunodeficiency Syndrome, Obesity, Pharmacotherapy + 2 more
Treatment
20 Active Studies for Marinol

What is Marinol

DronabinolThe Generic name of this drug
Treatment SummaryDronabinol (also known as Marinol) is a synthetic form of THC, the main active component in marijuana. It works by activating cannabinoid receptors in the body, which can lead to increased appetite, reduced pain, and changes in emotions and thinking. Dronabinol is used to treat anorexia related to weight loss in people with AIDS, and also to reduce nausea and vomiting caused by cancer chemotherapy that has not responded to other treatments. THC and CBD are two active cannabinoids found in marijuana that work differently on cannabinoid receptors in the body. Dronabinol can be synthesized from THC and CBD precursors and activated
Dronabinolis the brand name
image of different drug pills on a surface
Marinol Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Dronabinol
Dronabinol
1994
62

Effectiveness

How Marinol Affects PatientsTaking dronabinol can cause a rapid heart rate, redness in the eyes, and fluctuations in blood pressure. It can also affect mood, thinking, memory and perception, with higher doses causing more of these effects. The effects usually start around 30 minutes after taking the drug and last for 4 to 6 hours, but the appetite stimulant effect can last even longer. With long-term use, people can become tolerant to the effects on the heart and central nervous system, but not to the appetite stimulant effect. In studies of AIDS patients taking the recommended dosage, the appetite stimulant effect was still present after 5 months.
How Marinol works in the bodyDronabinol is a synthetic form of delta-9-tetrahydrocannabinol, the main active ingredient found in marijuana. It works by activating Cannabinoid-1 and Cannabinoid-2 receptors, which can reduce pain, increase appetite, and alter emotions and thinking.

When to interrupt dosage

The proposed measure of Marinol is contingent upon the recognized condition, including Unintentional Weight Loss, Pharmacotherapy and Acquired Immunodeficiency Syndrome. The amount of dosage is contingent upon the method of administration (e.g. Buccal or Capsule - Oral) specified in the table below.
Condition
Dosage
Administration
Pharmacotherapy
, 2.5 mg, 10.0 mg, 5.0 mg, 5.0 mg/mL, 2.7 mg/pump actuation
, Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Spray - Buccal, Buccal, Spray, Solution, Solution - Oral
Anorexia
, 2.5 mg, 10.0 mg, 5.0 mg, 5.0 mg/mL, 2.7 mg/pump actuation
, Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Spray - Buccal, Buccal, Spray, Solution, Solution - Oral
Acquired Immunodeficiency Syndrome
, 2.5 mg, 10.0 mg, 5.0 mg, 5.0 mg/mL, 2.7 mg/pump actuation
, Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Spray - Buccal, Buccal, Spray, Solution, Solution - Oral
Obesity
, 2.5 mg, 10.0 mg, 5.0 mg, 5.0 mg/mL, 2.7 mg/pump actuation
, Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Spray - Buccal, Buccal, Spray, Solution, Solution - Oral
Disease
, 2.5 mg, 10.0 mg, 5.0 mg, 5.0 mg/mL, 2.7 mg/pump actuation
, Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Spray - Buccal, Buccal, Spray, Solution, Solution - Oral

Warnings

Marinol Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Marinol.
Common Marinol Drug Interactions
Drug Name
Risk Level
Description
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Dronabinol.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Dronabinol.
Anagrelide
Major
The metabolism of Anagrelide can be decreased when combined with Dronabinol.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Dronabinol.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Dronabinol.
Marinol Toxicity & Overdose RiskTaking SYNDROS during pregnancy could harm the baby, so it should be avoided. Studies in animals showed that high doses of SYNDROS caused harm to unborn babies. The risk of birth defects and miscarriage for anyone taking SYNDROS is unknown. For mothers with HIV, breastfeeding should be avoided to prevent passing on the virus. There is not enough evidence to know how SYNDROS affects breastfeeding infants. Studies show that children may be more sensitive to the effects of SYNDROS than adults, so it should be used cautiously in children. The ingredients in SYNDROS (alcohol and propylene glycol)
image of a doctor in a lab doing drug, clinical research

Marinol Novel Uses: Which Conditions Have a Clinical Trial Featuring Marinol?

137 active clinical trials are currently assessing the potential of Marinol as a Pharmacotherapy, for Unintentional Weight Loss, and as an adjunct to conventional therapy in cases of inadequate response.
Condition
Clinical Trials
Trial Phases
Disease
0 Actively Recruiting
Acquired Immunodeficiency Syndrome
4 Actively Recruiting
Phase 1, Phase 2, Not Applicable
Pharmacotherapy
1 Actively Recruiting
Not Applicable
Anorexia
1 Actively Recruiting
Phase 1
Obesity
45 Actively Recruiting
Phase 2, Not Applicable, Phase 4, Phase 3, Phase 1

Marinol Reviews: What are patients saying about Marinol?

5Patient Review
10/30/2014
Marinol for Increased Hunger
This medication has been crucial in helping me recover from chemotherapy.
5Patient Review
4/26/2014
Marinol for Loss of Appetite with HIV
This treatment is incredibly effective against cancer cells.
4.7Patient Review
9/3/2014
Marinol for Loss of Appetite with HIV
This treatment has been effective in reducing the severity of my migraines, as well as the accompanying nausea. It has also helped to clear the fog of depression and restore my creativity and focus. However, I would caution anyone using this medication to be careful when driving or operating heavy machinery while they are still adjusting to the dosage.
4.7Patient Review
10/3/2016
Marinol for Nausea and Vomiting caused by Cancer Drugs
I'm currently battling ALS, and this drug has been a huge help. It's kept my appetite up and helped me to avoid depression. I feel like it's given me more time to prepare for the worst and find a good place that serves easy-to-eat burgers.
4.3Patient Review
3/8/2019
Marinol for Nausea and Vomiting caused by Cancer Drugs
This medication does a great job at alleviating pain. I also found that it helped me sleep better, which was an added bonus. Overall, I'm more than satisfied with this product.
4Patient Review
1/7/2013
Marinol for Nausea and Vomiting caused by Cancer Drugs
3Patient Review
4/27/2013
Marinol for Increased Hunger
2.7Patient Review
11/28/2013
Marinol for Nausea and Vomiting caused by Cancer Drugs
I experienced rapid weight loss with no appetite for the first five months. However, this drug then helped me gain my weight back. I'm grateful to not look anorexic anymore.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about marinol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What class of drug is Marinol?

"Marinol is used to relieve symptoms of nausea and vomiting, as well as appetite loss. It may be used alone or with other medications. Marinol belongs to a class of drugs called antiemetic agents."

Answered by AI

Is Marinol a narcotic?

"In the United States, Marinol is a non-narcotic drug that is available by prescription and is considered to have a low risk of physical or mental dependence."

Answered by AI

What is Marinol prescribed for?

"Dronabinol is a drug used to treat nausea and vomiting caused by cancer chemotherapy. It is typically only used when other drugs designed to control nausea and vomiting have not been successful. Additionally, dronabinol is used to treat loss of appetite and weight loss in patients with HIV infection."

Answered by AI

How does Marinol make u feel?

"Dronabinol (Marinol) can cause people to feel high, see or hear things that aren't there, feel paranoid, or feel like they're in a dream, especially at higher doses used to treat nausea and vomiting."

Answered by AI

Clinical Trials for Marinol

Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of Mayo Clinic in Rochester, United States.

Weight Loss Medications for Obesity in Bipolar Disorder

18 - 65
All Sexes
Rochester, MN
The goal of this clinical trial is to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss, and to study the effect of individualized guided medication in patients with bipolar disorder ages 18-65. The main questions it aims to answer are: * Can the investigators compare the distribution of obesity characteristics (hungry brain, hungry gut, emotional hunger) between bipolar patients and non-bipolar participants (comparing from IRB #24-002375)? * Can the investigators evaluate the feasibility of anti-obesity medication (AOM) in patients with bipolar disorder? Participation will last for about 17-18 weeks and includes 7 in-person study visits, 4 phone call visits, and 12 virtual group therapy sessions. The first visit lasts about 2 hours and includes going over the informed consent form, a diagnostic interview to confirm diagnosis, gathering vital signs, mood questionnaires, an ECG, and urine drug and pregnancy tests (if applicable). The second visit lasts about 6-7 hours and involves multiple procedures and completing questionnaires to determine which study drug would allow participants to lose weight most effectively. At the third visit, participants will be assigned to take one of three FDA approved medications for weight loss: Semaglutide (Wegovy®), Naltrexone/Bupropion (Contrave®), or Phentermine/Topiramate (Qysmia®). It is possible that participants could be assigned to a group that receives no study medication. All participants will be enrolled in a 12-week virtual group therapy program targeted for weight loss. On this third visit the investigators will also gather vital signs, and participants will give a sample of blood. After the third visit, participants will come in for study visits every 4 weeks for 16 weeks (4 visits) to assess medication adherence, vitals, and answer questions about mood and eating (participants will also give a sample of blood at the 8-week and 16-week visits). Every two weeks in between in-person visits, the study team will call participants to assess medication adherence. Participants will be compensated for time spent in this study.
Phase 4
Waitlist Available
Mayo ClinicMark A Frye, M.D.
Have you considered Marinol clinical trials? We made a collection of clinical trials featuring Marinol, we think they might fit your search criteria.Go to Trials
Image of Stanford University School of Medicine in Palo Alto, United States.

Dietary Strategies for Obesity

18+
All Sexes
Palo Alto, CA
The goal of the Reset trial is to learn about the optimal combination of dietary behavior strategies in a fully digital weight loss intervention. The intervention is designed for adults with overweight or obesity. The investigators will examine the impact on weight loss of four dietary strategies: 1) limiting Red Zone Foods (i.e., foods that are high in calories and low in nutrition), 2) limiting eating windows, 3) increasing protein intake, and 4) increasing fiber intake. Each of these strategies will include goal setting, daily self-monitoring, and tailored feedback. The investigators will recruit 208 participants. Broadly, adults with overweight or obesity who live in the U.S. will be eligible. The weight loss intervention will last 12 weeks. All participants will be asked to track their body weight daily and complete weekly behavioral lessons and action plans to promote healthy eating and physical activity. All study tasks will occur remotely. Assessment of body weight and survey measures will occur at the beginning of the trial ("baseline"), and at 1 month and 3 months. The Multiphase Optimization Strategy (MOST) framework will be used to identify which combination of the dietary behavior strategies results in the greatest weight loss. In total, there will be 16 treatment conditions.
Waitlist Available
Has No Placebo
Stanford University School of MedicineMichele L Patel, PhD
Image of University of South Florida in Tampa, United States.

TORe + Lifestyle Changes for Weight Regain

18+
All Sexes
Tampa, FL
The goal of this clinical trial is to evaluate weight loss with TORe and intensive lifestyle modification versus intensive lifestyle modification alone in subjects who have regained weight following a Roux-en-Y gastric bypass. Participants will randomized 2:1. Those randomized to the TORe arm will receive a TORe procedure and intensive lifestyle modification which consists of a well-balanced calorie restrictive diet, incorporation of exercise and coaching on lifestyle discussion. Participants randomized the lifestyle modification alone arm will be eligible to receive a TORe procedure at 6 months post enrollment. Total follow up will be 24 months.
Waitlist Available
Has No Placebo
University of South Florida (+9 Sites)Boston Scientific Corporation
Image of Rutgers University - NJ Inst Food Nutrition & Health in New Brunswick, United States.

Peanut Snacks for Weight Loss

50 - 75
All Sexes
New Brunswick, NJ
The aging population is rapidly increasing, and it is important to identify dietary factors that can prevent disease and promote health in this group. Legumes, such as peanuts, are a plant-based food high in protein and unsaturated fat making this a healthy choice but are not consumed frequently enough in older adults. Studies have shown that regular nut consumption is associated with lower adiposity and reduced weight gain, and several dietary pattern studies indicate that nuts and legumes are associated with better bone health. In addition, our preliminary translational data indicates that a higher monounsaturated fatty acid (MUFA) intake is associated with improved bone mineral density (BMD) and quality. Given these findings, the proposed study aims to examine the impact of consuming peanut products on bone health, metabolic health (e.g., serum glucose, insulin, lipids and inflammation), markers of brain and sleep health, and physical function in overweight and obese older adults before and after a six-month weight loss intervention using a randomized controlled design. The results of this study have the potential to provide valuable insights into the role of peanuts as a sources of fatty acids in promoting health and preventing disease in at-risk adults.
Recruiting
Has No Placebo
Rutgers University - NJ Inst Food Nutrition & Health
Have you considered Marinol clinical trials? We made a collection of clinical trials featuring Marinol, we think they might fit your search criteria.Go to Trials
Image of The Hospital for Sick Children in Toronto, Canada.

ML-Based Intervention for Vomiting in Pediatric Cancer

Any Age
All Sexes
Toronto, Canada
The goal of this single arm trial is to learn if a machine learning (ML) model predicting the risk of vomiting within the next 96 hours will impact vomiting outcomes in inpatient cancer pediatric patients. The main questions it aims to answer are whether an ML model predicting the risk of vomiting within the next 96 hours will: Primary 1\. Reduce the proportion with any vomiting within the 96-hour window Secondary 1. Reduce the number of vomiting episodes 2. Increase the proportion receiving care pathway-consistent care 3. Impact on number of administrations and costs of antiemetic medications Newly admitted participants will have a ML model predict the risk of vomiting within the next 96 hours according to their medical admission information. The prediction will be made at 8:30 AM following admission. Pharmacists will be charged with bringing information about patients' vomiting risk to the attention of the medical team and implementing interventions.
Recruiting
Has No Placebo
The Hospital for Sick ChildrenSantiago Arciniegas, MSc
Image of University of Texas Health Science Center at San Antonio in San Antonio, United States.

Tirzepatide for Muscle Health

18+
All Sexes
San Antonio, TX
Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist recently approved for the treatment of T2DM and obesity has been shown to be effective at reducing weight, improving markers of T2DM control, and improving cardiovascular health. Utilization of tirzepatide among older adults has been on the rise since FDA approval was issued, however the effects of tirzepatide use on functional outcomes in older adults with obesity are not well established. Recent studies show that weight loss caused by tirzepatide may be driven by substantial loss of lean muscle mass, which may contribute to weakness and frailty, particularly among older adults. The proposed pilot study aims to evaluate how treatment with tirzepatide for 6 months affects muscle mass and function among older adults, and if changes in muscle mass are linked to changes in functional status over the same time period.
Phase 2
Waitlist Available
University of Texas Health Science Center at San AntonioShreya Rao, MD, MPH
Image of LEAF Weight Managment Clinic in Ottawa, Canada.

Contrave for Obesity

18 - 64
All Sexes
Ottawa, Canada
Obesity is a common chronic disease linked with increased risk for other illnesses and earlier death. Our team and others have shown that many bodily and psychological changes occur when individuals are on calorie-restricted diets. These changes might undermine dietary adherence and help to explain the relatively poor long-term efficacy of diets. These include increased appetite, increased food 'value' and 'wanting' that leads to overconsumption. Other factors include more sensitive sensory cues (e.g., smelling), higher food liking and craving, and a drop in resting energy expenditure (REE). REE has been shown to predict weight regain. The standard care for obesity may include the use of the weight-loss drug CONTRAVE®. The Federal Drug Agency (FDA) and Health Canada have approved this drug for weight management and obesity treatment. Although CONTRAVE® was designed to reduce appetite, food-related impulsivity and cravings, its mechanisms of action are unclear. In other words, the effects of CONTRAVE® on REE, executive function, and brain changes remain unknown in humans. A better understanding of how this drug works on the brain and body could lead to improvements in obesity management in the future. As such, the goal of this research is to study the effects of 4 weeks of CONTRAVE® (+ diet program) vs. control (placebo pill + diet program) on mood, body composition changes, biological/metabolic measures, and brain measures. Adults aged 18-64 with obesity will be randomized to one of two groups: diet + CONTRAVE® (CONTRAVE®, 20 participants) or diet + Placebo (Placebo, 20 participants). Both groups will be assigned the same study procedures for the entire study duration. The only difference is that Group 1 will receive CONTRAVE® while Group 2 will receive a placebo (non-medical) pill. The study design and intervention is as follows: Participants who meet all the telephone screening criteria will be invited to the Clinical EEG \& Neuroimaging Laboratory at The Royal's IMHR for an in-person screening and test-dose session. Participants who are cleared by the study physician, Dr. Pierre Blier, during the in-person screening will be enrolled in the 4-weeks trial. After the in-person screening visit, participants will attend two baseline testing visits (before starting the medication + diet program). The first will occur at the Behavioural and Metabolic Research Unit at the University of Ottawa. During this in-person visit, measures of body composition, resting energy expenditure, appetite, food craving, impulsivity, eating behaviours, taste and odour sensitivity, energy intake, and food preference will be collected. The second baseline visit (within a week of the first one) will occur at The Royal/IMHR. During this visit, participants will be asked to complete questionnaires. They will undergo an EEG recording while resting and performing computer tasks. They will also get a brain imaging scan, during which they are asked to rest and complete a computer task. Both testing sessions (University of Ottawa and Royal Ottawa testing sessions) will be repeated after four weeks of treatment. The section below provides further description and timing of these visits. As part of the treatment, you will receive an individualized dietary intervention with appropriate energy restriction from a registered dietitian at Dr. Judy Shiau's LEAF weight management clinic (called the 4-week BUDS program). The program involves weekly touch points with a registered dietitian and meal planning/coaching. The diet intervention will commence the same week as the start of the placebo/CONTRAVE®. During the 4-week intervention, participants will be asked to complete online questionnaires at various times.
Phase 4
Recruiting
LEAF Weight Managment Clinic (+2 Sites)Pierre Blier, M.D., Ph.D
Have you considered Marinol clinical trials? We made a collection of clinical trials featuring Marinol, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security